Analysts’ views on Sanofi
Sanofi, a global healthcare leader, has a comprehensive product portfolio and pipeline focusing on immunology, oncology, multiple sclerosis, neurology, rare disease disorders, diabetes, cardiovascular diseases, vaccines, and infectious diseases. In Q1 2018, the company’s sales fell and its missed analysts’ estimates. Let’s begin by looking at analysts’ recommendations for SNY stock for the next 12 months.
Of the five analysts covering SNY stock on June 27, two recommended “strong buy,” and three recommended “hold.” There were no “sell” recommendations despite the company’s lackluster performance over the recent quarters. Their consensus target price for SNY stock is $44, which implies a ~9.5% return over the next year based on SNY’s June 26 closing price of $40.23.
Analysts’ average target prices for peers GlaxoSmithKline (GSK), Novo Nordisk (NVO), and Eli Lilly (LLY) are $42.13, $60.40, and $91.26, respectively, implying 5.2%, 32.8%, and 7.2% returns over the next 12 months.
Barclays updates its target price for Sanofi
On June 25, Barclays gave Sanofi a price target of 60 euros while maintaining a “sell” rating. This target price represents a ~9.3% downside based on its current stock price. In the next article, we’ll look at Sanofi’s valuation.
Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!